Patients with gastroenteropancreatic neuroendocrine tumors may benefit from treatment with radionucleotide therapeutic 177Lu-edotreotide, which received fast track designation from the FDA.

Latest CME Events & Activities

42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®

November 13-15, 2024

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

42nd Annual Miami Breast Cancer Conference®

March 6 - 9, 2025

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

18th Annual New York GU Cancers Congress™

March 28-29, 2025

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777